Pfizer Inc (PFE) Closes 1.74% Down on the Day for January 13

Equities Staff |

Dow Jones component Pfizer Inc (PFE) saw its stock move -1.74% to $30.46, representing a per-share move of $0.54, on volume of 24.96 million shares for Wednesday.

Pfizer Inc currently has a total float of 6.17 billion shares and moves 34.04 million a day, on average. The stock opened at $31.09 on January 13 and traded between a low of $30.27 and a high of $31.28. The stock now has a 50-day SMA of $32.68 and 200-day SMA of $33.33, and it has a high of $36.46 and low of $28.47 over the last year.

Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.

Based out of New York, NY, Pfizer Inc has 78,300 employees and is helmed by CEO Ian C. Read.

For a deeper dive into the fundamentals of Pfizer Inc, check out’s E.V.A. report for PFE.


The Dow Jones Industrial Average is the oldest and most-often cited stock market index for the American equities market. While it’s arguably outdated and inefficient, it remains the most visible representation of the stock market to the outside world. Consisting of 30 companies selected by the editorial board of the Wall Street Journal, it’s meant to give an overview of stock performances by looking at a slice of those mega- and large-cap companies deemed to best represent the broad economy.

The history of the index dates all the way back to 1896 when it was first created by Charles Dow, the legendary founding editor of the Wall Street Journal and founder of Dow Jones & Company, and Edward Jones, a statistician. The price-weighted, scaled index has since become a standard part of most major daily news recaps and has seen dozens of different companies pass through its ranks, with only General Electric (GE) remaining on the index since its inception.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Relevium Technologies Inc.

Relevium Technologies Inc is engaged in the acquisition of products, technologies and businesses relating to musculoskeletal function, specifically Pain Relief, Injury Recovery and Active Performance.

Private Markets

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.


Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…